2.5 million people in India to benefit from accessible, quality care as Abbott upgrades 75 healthcare centers; aiming to help the Modi...

Keytruda met the primary endpoint in the Phase 3 KEYNOTE-859 trial in patients with HER2-negative gastric cancer. Merck announced that...